Biotech Values

[WorstLuck]

That they showed a P value for separation of placebo and 200 mg was extremely disingenuous. There was no valid statistical examination for that data set. And a drop of 30 µm from a baseline of something over 300 µm in twelve weeks means nothing. You are in OCUL if I recall. The P1 they ran in Australia had a small cohort of treatment naive AMD patients drop from 484 baseline to 232 over the same time frame picking up 17 letters BCVA in the process.

Just to clarify a point or two - DME symptoms wax and wane. It's more difficult to get a statistical evaluation of a treatment than in wAMD. The idea of getting useful information in a small 12 week trial in DME is silly. EYPT just had a ghastly 9 month readout from a 12 month DME P2 trial, and we know the drug is active. But, RZLT gets no benefit of the doubt.